Hepatitis B virus with the rtL80V/I mutation is associated with a poor response to adefovir dipivoxil therapy

Liver International

Volumn 29, Issue 4, 2009, Pages 552-556

  Lee, Yoon Seon ^a   Chung, Young Hwa ^a   Kim, Jeong A ^a   Kim, Sung Eun ^a   Shin, Jung Woo ^a   Kim, Kang Mo ^a   Lim, Young Suk ^a   Park, Neung Hwa ^a   Lee, Han Chu ^a   Lee, Yung Sang ^a   Suh, Dong Jin ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Adefovir dipivoxil; Chronic hepatitis B; rtL180M; rtL80V I; YMDD mutation

Indexed keywords

ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; ASPARTIC ACID; HEPATITIS B(E) ANTIGEN; ISOLEUCINE; LAMIVUDINE; LEUCINE; METHIONINE; TYROSINE; VALINE; VIRUS DNA;

ADULT; AGED; ARTICLE; DNA DETERMINATION; DRUG EFFICACY; DRUG RESPONSE; FEMALE; GENE IDENTIFICATION; GENE MUTATION; GENETIC VARIABILITY; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; TREATMENT DURATION;

ADENINE; ADULT; AGED; ANTIVIRAL AGENTS; DNA MUTATIONAL ANALYSIS; DNA, VIRAL; DRUG RESISTANCE, VIRAL; FEMALE; GENE PRODUCTS, POL; GENOTYPE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; MALE; MIDDLE AGED; MUTATION; PHOSPHONIC ACIDS; POLYMERASE CHAIN REACTION; RECOVERY OF FUNCTION; VIRAL LOAD; YOUNG ADULT;

EID: 62749177499     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2008.01882.x     Document Type: Article

References (29)

1. Beasley R, Hwang L, Lin C, et al. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22707 men in Taiwan. Lancet 1981; 21: 1129-33.
2. Dienstag J, Schiff E, Wright T, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999; 341: 1256-63.
3. Lai C, Chien R, Leung N, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998; 339: 61-8.
4. Lai C, Dienstag J, Schiff E, et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 2003; 36: 687-96.
5. Leung N, Lai C, Chang T, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: Results after 3 years of therapy. Hepatology 2001; 33: 1527-32.
6. Liaw Y, Leung N, Chang T, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Gastroenterology 2000; 119: 172-80.
7. Allen M, Deslauriers M, Andrews C, et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Hepatology 1998; 27: 1670-7.
8. Delaney W IV, Yang H, Westland C, et al. The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro. J Virol 2003; 77: 11833-41.
9. Ogata N, Fujii K, Takigawa S, et al. Novel patterns of amino acid mutations in the hepatitis B virus polymerase in association with resistance to lamivudine therapy in Japanese patients with chronic hepatitis B. J Med Virol 1999; 59: 270-6.
10. Bartholomeusz A, Locarnini SA. Antiviral drug resistance: Clinical consequences and molecular aspects. Semin Liver Dis 2006; 26: 162-70.
11. Lok A, McMahon B. Chronic hepatitis B: Update of recommendations. Hepatology 2004; 39: 857-61.
12. Schiff E, Lai C, Hadziyannis S, et al. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology 2003; 38: 1419-27.
13. Westland C, Yang H, Delaney W IV, et al. Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B. Hepatology 2003; 38: 96-103.
14. Lee YS, Suh DJ, Lim YS, et al. Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Hepatology 2006; 43: 1385-91.
15. Chan HL, Chui AK, Lau WY, et al. Factors associated with viral breakthrough in lamivudine monoprophylaxis of hepatitis B virus recurrence after liver transplantation. J Med Virol 2002; 68: 182-7.
16. Lindh M, Andersson AS, Gusdal A. Genotypes, nt 1858 variants, and geographic origin of hepatitis B virus -large-scale analysis using a new genotyping method. J Infect Dis 1997; 175: 1285-93.
17. Cane PA, Mutimer D, Ratcliffe D, et al. Analysis of hepatitis B virus quasispecies changes during emergence and reversion of lamivudine resistance in liver transplantation. Antivir Ther 1999; 4: 7-14.
18. Cooley L, Ayres A, Bartholomeusz A, et al. Prevalence and characterization of lamivudine-resistant hepatitis B virus mutations in HIV-HBV co-infected individuals. AIDS 2003; 17: 1649-57.
19. Warner N, Locarnini S, Kuiper M, et al. The L80I substitution in the reverse transcriptase domain of the hepatitis B virus polymerase is associated with lamivudine resistance and enhanced viral replication in vitro. Antimicrob Agents Chemother 2007; 51: 2285-92.
20. Hadziyannis S, Tassopoulos N, Heathcote E, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003; 348: 800-7.
21. Marcellin P, Chang T, Lim S, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003; 348: 808-16.
22. Perrillo R, Schiff E, Yoshida E, et al. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 2000; 32: 129-34.
23. Buti M, Elefsiniotis I, Jardi R, et al. Viral genotype and baseline load predict the response to adefovir treatment in lamivudine-resistant chronic hepatitis B patients. J Hepatol 2007; 47: 366-72.
24. Ono-Nita SK, Kato N, Shiratori Y, et al. Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitors. J Clin Invest 1999; 103: 1635-40.
25. Westland C, Yang H, Delaney W IV, et al. Activity of adefovir dipivoxil against all patterns of lamivudine-resistant hepatitis B viruses in patients. J Viral Hepat 2005; 12: 67-73.
26. Chan HL, Wong VW, Tse CH, et al. Early virological suppression is associated with good maintained response to adefovir dipivoxil in lamivudine resistant chronic hepatitis B. Aliment Pharmacol Ther 2007; 25: 891-8.
27. Suzuki Y, Yotsuyanagi H, Okuse C, et al. Fatal liver failure caused by reactivation of lamivudine-resistant hepatitis B virus: A case report. World J Gastroenterol 2007; 13: 964-9.
28. Lada O, Benhamou Y, Cahour A, et al. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir. Antivir Ther 2004; 9: 353-63.
29. Yang H, Qi X, Sabogal A, et al. Cross-resistance testing of next-generation nucleoside and nucleotide analogues against lamivudine-resistant HBV. Antivir Ther 2005; 10: 625-33.